Generate Biomedicines, Inc. (GENB) Stock Analysis
A live, multi-source view of Generate Biomedicines, Inc. (GENB): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 312 employees · generatebiomedicines.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Generate Biomedicines, Inc. (GENB) had a market capitalization of $2.10B (forward -7.2); the shares traded in a 52-week range of $11.00 – $22.67 (29.2% over the year).
- Market cap
- $2.10B
- Enterprise value
- $1.71B
- Forward P/E
- -7.2
- Price / book
- 4.61
- EPS (trailing)
- $-2.10
- EPS (forward)
- $-2.28
- Payout ratio
- 0.0%
- 52-week range
- $11.00 – $22.67
- 52-week change
- 29.2%
- Average volume
- 997,441
- Shares outstanding
- 128.4M
- Short % of float
- 9.74%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Generate Biomedicines, Inc. (GENB) last closed at $15.52 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -4.0% versus its 20-day average, 20-day versus 50-day average spread +6.3%, MACD histogram -0.14.
Sentiment inputs: 33% of recent Finnhub-scored headlines read bullish; StockTwits 77% bullish; analyst consensus score 83/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of GENB; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Frances Arnold (0B/1S). Who is trading what
RapidTradeView pick record
GENB has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Generate Biomedicines, Inc. (GENB) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell GENB.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.